[go: up one dir, main page]

PL2698165T3 - Cytotoksyczna immunoglobulina - Google Patents

Cytotoksyczna immunoglobulina

Info

Publication number
PL2698165T3
PL2698165T3 PL13180006T PL13180006T PL2698165T3 PL 2698165 T3 PL2698165 T3 PL 2698165T3 PL 13180006 T PL13180006 T PL 13180006T PL 13180006 T PL13180006 T PL 13180006T PL 2698165 T3 PL2698165 T3 PL 2698165T3
Authority
PL
Poland
Prior art keywords
immunoglobulin
cytotoxic
cytotoxic immunoglobulin
Prior art date
Application number
PL13180006T
Other languages
English (en)
Inventor
Gottfried Himmler
Geert Mudde
Anton Bauer
Gerda Redl
Florian Rueker
Gordana Wozniak-Knopp
Maximilian Woisetschlaeger
Original Assignee
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H filed Critical F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H
Publication of PL2698165T3 publication Critical patent/PL2698165T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL13180006T 2008-05-02 2009-03-03 Cytotoksyczna immunoglobulina PL2698165T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08450068A EP2113255A1 (en) 2008-05-02 2008-05-02 Cytotoxic immunoglobulin
EP09737920.0A EP2274012B1 (en) 2008-05-02 2009-03-03 Cytotoxic immunoglobulin
EP13180006.2A EP2698165B1 (en) 2008-05-02 2009-03-03 Cytotoxic immunoglobulin

Publications (1)

Publication Number Publication Date
PL2698165T3 true PL2698165T3 (pl) 2018-10-31

Family

ID=39745473

Family Applications (3)

Application Number Title Priority Date Filing Date
PL09737920T PL2274012T3 (pl) 2008-05-02 2009-03-03 Cytotoksyczna immunoglobulina
PL13167714T PL2630970T3 (pl) 2008-05-02 2009-03-03 Cytotoksyczna immunoglobulina
PL13180006T PL2698165T3 (pl) 2008-05-02 2009-03-03 Cytotoksyczna immunoglobulina

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL09737920T PL2274012T3 (pl) 2008-05-02 2009-03-03 Cytotoksyczna immunoglobulina
PL13167714T PL2630970T3 (pl) 2008-05-02 2009-03-03 Cytotoksyczna immunoglobulina

Country Status (15)

Country Link
US (4) US8859738B2 (pl)
EP (4) EP2113255A1 (pl)
JP (2) JP5693447B2 (pl)
CN (2) CN106397595A (pl)
CA (1) CA2721614C (pl)
CY (1) CY1119508T1 (pl)
DK (3) DK2630970T3 (pl)
ES (3) ES2490192T3 (pl)
HR (3) HRP20140760T1 (pl)
HU (2) HUE039975T2 (pl)
LT (2) LT2698165T (pl)
PL (3) PL2274012T3 (pl)
PT (1) PT2630970T (pl)
SI (2) SI2630970T1 (pl)
WO (1) WO2009132876A1 (pl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320374T3 (es) 2005-01-05 2009-05-21 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Dominios de inmunoglobulina sintetica con propiedades de enlace modificadas en regiones de la molecula diferentes de las regiones de determinacion de complementariedad.
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP2438962A3 (en) 2006-02-13 2012-07-18 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
JP5602625B2 (ja) 2007-06-26 2014-10-08 エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング 結合物質のディスプレイ
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
BRPI0821906B1 (pt) 2008-01-03 2022-06-07 The Scripps Research Institute Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US20120010388A1 (en) * 2010-04-16 2012-01-12 Gottfried Himmler LeY SPECIFIC BIOTHERAPEUTIC
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
ES2749200T3 (es) * 2012-05-10 2020-03-19 Bioatla Llc Anticuerpos monoclonales multiespecíficos
KR20150036274A (ko) 2012-07-19 2015-04-07 알레시아 바이오쎄라퓨틱스 인코포레이티드 항-siglec-15 항체
EP2943512A4 (en) 2013-01-11 2016-06-01 California Inst Biomedical Res BOVINE FUSION ANTIBODY
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
EP3019531A4 (en) 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
EP3722442B1 (en) 2013-08-05 2023-04-05 Twist Bioscience Corporation De novo synthesized gene libraries
GB201317622D0 (en) * 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
AP2016009586A0 (en) 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
SG11201702310QA (en) 2014-09-26 2017-04-27 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
TWI565712B (zh) * 2014-10-20 2017-01-11 福又達生物科技股份有限公司 增進神經元生長的胜肽及其應用
TWI688572B (zh) 2015-01-26 2020-03-21 美商宏觀基因股份有限公司 包含dr5-結合結構域的多價分子
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
GEAP202215554A (en) 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
CA2998169A1 (en) 2015-09-18 2017-03-23 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
US11512347B2 (en) 2015-09-22 2022-11-29 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
AU2016334041B2 (en) 2015-10-08 2023-02-09 Macrogenics, Inc. Combination therapy for the treatment of cancer
MX2018007089A (es) 2015-12-14 2019-01-30 Macrogenics Inc Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
US20170233472A1 (en) 2016-02-17 2017-08-17 Macrogenics, Inc. ROR1-Binding Molecules, and Methods of Use Thereof
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
CN109563171B (zh) 2016-06-20 2023-09-19 F-星治疗有限公司 结合pd-l1和lag-3的结合分子
ES3010640T3 (en) * 2016-06-20 2025-04-04 Invox Pharma Ltd Lag-3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN110248724B (zh) 2016-09-21 2022-11-18 特韦斯特生物科学公司 基于核酸的数据存储
WO2018119166A1 (en) 2016-12-23 2018-06-28 Macrogenics, Inc. Adam9-binding molecules, and methods of use thereof
GB201700345D0 (en) * 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
NZ756763A (en) 2017-02-17 2023-04-28 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
SG11201907713WA (en) 2017-02-22 2019-09-27 Twist Bioscience Corp Nucleic acid based data storage
MX2019009967A (es) 2017-02-24 2019-12-02 Macrogenics Inc Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for assembling continuous nucleic acids
WO2019051501A1 (en) 2017-09-11 2019-03-14 Twist Bioscience Corporation PROTEINS BINDING TO GPCR AND METHODS OF SYNTHESIS
EP3692060A1 (en) 2017-10-03 2020-08-12 Merck Patent GmbH Cysteine engineered antigen-binding molecules
EP3697529B1 (en) 2017-10-20 2023-05-24 Twist Bioscience Corporation Heated nanowells for polynucleotide synthesis
RU2020122822A (ru) 2017-12-12 2022-01-13 Макродженикс, Инк. Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
AU2018387741B2 (en) 2017-12-19 2025-09-25 Invox Pharma Limited FC binding fragments comprising a PD-L1 antigen-binding site
CA3088911A1 (en) 2018-01-04 2019-07-11 Twist Bioscience Corporation Dna-based storage device and method for synthesizing polynucleotides using the device
EP3752196A4 (en) 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
US10640576B2 (en) 2018-04-10 2020-05-05 Y-Biologics Inc. Cell engaging binding molecules
IL278771B2 (en) 2018-05-18 2025-09-01 Twist Bioscience Corp Polynucleotides, reagents and methods for nucleic acid hybridization
CA3103414A1 (en) 2018-06-14 2019-12-19 Bioatla, Inc. Multi-specific antibody constructs
SG11202100172XA (en) 2018-07-12 2021-02-25 F Star Beta Ltd Antibody molecules that bind cd137 and ox40
CN112423845B (zh) 2018-07-12 2024-07-30 F-星治疗有限公司 结合pd-l1和cd137的抗体分子
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
US12357959B2 (en) 2018-12-26 2025-07-15 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN115925972A (zh) * 2019-02-18 2023-04-07 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
KR20210143766A (ko) 2019-02-26 2021-11-29 트위스트 바이오사이언스 코포레이션 Glp1 수용체에 대한 변이체 핵산 라이브러리
US11492728B2 (en) 2019-02-26 2022-11-08 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
JP2022550497A (ja) 2019-06-21 2022-12-02 ツイスト バイオサイエンス コーポレーション バーコードに基づいた核酸配列アセンブリ
EP4464827A3 (en) 2019-09-23 2025-02-26 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US20240279353A1 (en) 2020-07-06 2024-08-22 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
US20250281633A1 (en) 2021-05-03 2025-09-11 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
CN117999101A (zh) 2021-05-25 2024-05-07 默克专利股份公司 靶向EGFR的Fc抗原结合片段-药物缀合物
AU2023329054A1 (en) 2022-08-26 2025-04-03 Merck Patent Gmbh Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor
CN119836301A (zh) 2022-08-26 2025-04-15 默克专利股份公司 包括抗msln/cd137抗体和化疗剂的癌症治疗

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003947A1 (en) 1984-03-01 1985-09-12 The Board Of Trustees Of The Leland Stanford Jr. U T-cell receptor-specific for antigen polypeptides and related polynucleotides
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
EP0229046B1 (fr) 1985-03-30 1994-05-04 BALLIVET, Marc Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP3283041B2 (ja) 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
EP0640130B1 (en) 1992-05-08 1998-04-15 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
DE69522216T2 (de) 1994-05-13 2002-05-02 Biovation Ltd Zielzellen-bindende chimäre Peptide
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
AU6685698A (en) 1997-03-07 1998-09-22 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6180343B1 (en) 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
AU3210100A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
AU3719500A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
JP4387625B2 (ja) * 1999-07-02 2009-12-16 ジェネンテック・インコーポレーテッド Ｈｅｒ２に結合する化合物
MXPA02005559A (es) 1999-12-06 2004-09-10 Univ Illinois Proteinas de tcr de alta afinidad y metodos.
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
WO2001070947A2 (en) 2000-03-20 2001-09-27 Maxygen, Inc. Method for generating recombinant dna molecules in complex mixtures
CA2407956A1 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
WO2001088159A2 (en) 2000-05-16 2001-11-22 Euro-Celtique S.A. Cd28 synthebody for the modulation of immune responses
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
WO2002006469A2 (en) 2000-07-18 2002-01-24 Enchira Biotechnology Corporation Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
JP2002058479A (ja) 2000-08-14 2002-02-26 Canon Inc 構造認識アミノ酸配列の取得方法
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
WO2002038602A2 (en) 2000-11-08 2002-05-16 Incyte Genomics, Inc. Secreted proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
WO2002059263A2 (en) 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
IL141539A0 (en) 2001-02-20 2002-03-10 Yeda Res & Dev Dna molecules and cells transfected therewith
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
CA2444854A1 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
EP1281757A1 (en) 2001-07-31 2003-02-05 Direvo Biotech AG Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids
NZ531208A (en) 2001-08-31 2005-08-26 Avidex Ltd Multivalent soluble T cell receptor (TCR) complexes
JP4578098B2 (ja) 2001-10-01 2010-11-10 ダイアックス、コープ 多重鎖真核ディスプレイベクターとその使用
EP1446418B1 (en) 2001-10-22 2012-05-23 The Scripps Research Institute Integrin targeting compounds
US20040043424A1 (en) 2001-11-15 2004-03-04 Baughn Mariah R Immunoglobulin superfamily proteins
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US20040063924A1 (en) 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
US20030157091A1 (en) 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
JP2005517718A (ja) 2002-02-19 2005-06-16 シンセリカ・コーポレイション 免疫応答および輸送の代替抗体による調整のための組成物および方法
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1487856B1 (en) * 2002-03-04 2010-07-28 Imclone LLC Human antibodies specific to kdr and uses thereof
US20040097711A1 (en) 2002-03-12 2004-05-20 Henry Yue Immunoglobulin superfamily proteins
EP1394251A1 (en) 2002-08-23 2004-03-03 Direvo Biotech AG Method for the selective randomization of polynucleotides
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
AU2003286263A1 (en) 2002-12-03 2004-06-23 Avidex Ltd. Complexes of receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
WO2005021595A1 (en) 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
CA2550551C (en) 2004-01-16 2013-10-29 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
KR20180004850A (ko) 2004-07-22 2018-01-12 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
ES2629397T3 (es) 2004-09-24 2017-08-09 Amgen Inc. Moléculas de Fc modificadas
WO2006037960A2 (en) 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
US20080274133A1 (en) 2004-11-18 2008-11-06 Avidex Ltd. Soluble Bifunctional Proteins
GB0425732D0 (en) 2004-11-23 2004-12-22 Avidex Ltd Gamma-delta t cell receptors
ES2320374T3 (es) 2005-01-05 2009-05-21 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Dominios de inmunoglobulina sintetica con propiedades de enlace modificadas en regiones de la molecula diferentes de las regiones de determinacion de complementariedad.
GB0503546D0 (en) 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP2007808A4 (en) 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
US7514271B2 (en) 2007-03-30 2009-04-07 International Business Machines Corporation Method of forming high density planar magnetic domain wall memory
EP1975178A1 (en) 2007-03-30 2008-10-01 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Transcytotic modular antibody
JP5602625B2 (ja) 2007-06-26 2014-10-08 エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング 結合物質のディスプレイ
US8580927B2 (en) 2008-01-31 2013-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered antibody constant domain molecules
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CA2765478A1 (en) 2009-07-09 2011-01-13 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Stabilized immunoglobulin constant domains
US20120010388A1 (en) 2010-04-16 2012-01-12 Gottfried Himmler LeY SPECIFIC BIOTHERAPEUTIC
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US20140087957A1 (en) * 2012-09-25 2014-03-27 Marko Vuskovic Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof

Also Published As

Publication number Publication date
EP2698165A1 (en) 2014-02-19
EP2630970B1 (en) 2016-11-02
US8859738B2 (en) 2014-10-14
US9255149B2 (en) 2016-02-09
JP2011521905A (ja) 2011-07-28
CA2721614A1 (en) 2009-11-05
SI2274012T1 (sl) 2014-08-29
WO2009132876A1 (en) 2009-11-05
EP2274012B1 (en) 2014-05-14
DK2274012T3 (da) 2014-08-18
CN102083464B (zh) 2016-08-03
EP2698165B1 (en) 2018-05-16
US20150166665A1 (en) 2015-06-18
JP2015028078A (ja) 2015-02-12
PL2630970T3 (pl) 2017-04-28
EP2630970A1 (en) 2013-08-28
LT2698165T (lt) 2018-11-26
ES2490192T3 (es) 2014-09-03
HRP20140760T1 (hr) 2014-11-07
CA2721614C (en) 2018-01-09
CN102083464A (zh) 2011-06-01
CN106397595A (zh) 2017-02-15
US10125197B2 (en) 2018-11-13
PL2274012T3 (pl) 2014-11-28
LT2630970T (lt) 2017-01-10
EP2113255A1 (en) 2009-11-04
HRP20161630T1 (hr) 2017-02-10
PT2630970T (pt) 2017-01-04
HRP20181267T1 (hr) 2018-10-05
SI2630970T1 (sl) 2017-01-31
ES2683847T3 (es) 2018-09-28
HUE039975T2 (hu) 2019-02-28
JP5693447B2 (ja) 2015-04-01
US20140364592A1 (en) 2014-12-11
ES2609359T3 (es) 2017-04-19
DK2698165T3 (en) 2018-08-13
US20110046355A1 (en) 2011-02-24
JP6138740B2 (ja) 2017-05-31
US20160176984A1 (en) 2016-06-23
DK2630970T3 (en) 2017-01-30
EP2274012A1 (en) 2011-01-19
HUE031447T2 (en) 2017-07-28
CY1119508T1 (el) 2018-03-07

Similar Documents

Publication Publication Date Title
HRP20181267T1 (hr) Citotoksični imunoglobulin
IL211180B (en) Attached polyethylene glycol and docetaxel
GB0821100D0 (en) Antibodies
GB0914691D0 (en) Immunoglobulin variants
ZA201006099B (en) Anti-tyrp1 antibodies
PL2254769T3 (pl) Okucie
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
GB0820166D0 (en) Former
EP2311493A4 (en) CYTOTOXIC COMPOSITION
GB0804970D0 (en) Birdfood wrapper
GB0902938D0 (en) Cytotoxic compounds
AU4098P (en) NPW2 Dianella tasmanica
AU3977P (en) PARV01 Myoporum parvifolium
AU3972P (en) Tobruk xTriticosecale
AU3935P (en) DPV308 Dianella prunina
GB0805182D0 (en) Jiggy pave
GB0704942D0 (en) Welding
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies
GB0819721D0 (en) Connecting means
AU323246S (en) Coffeemachine for coffeepods
GB0707693D0 (en) Travel application
GB0821899D0 (en) Easybrush it
GB0814118D0 (en) Property tycoon